Identifying and testing potential new anti-asthma agents

Bibliography

• Barnes PJ. New therapies for asthma: is there any progress? Trends Pharmacol Sci 2010;31(7):335-43
   PubMed Web of Science ®Google Scholar
• Hart TK, Blackburn MN, Brigham-Burke M, Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002;130(1):93-100
   PubMed Web of Science ®Google Scholar
• Corren J, Busse W, Meltzer EO, A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010;181(10):788-96
   PubMedGoogle Scholar
• Gauvreau GM, Boulet LP, Cockcroft DW, The effects of IL-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011;183(8):1007-14
   PubMed Web of Science ®Google Scholar
• Szymkowski DE. Creating the next generation of protein therapeutics through rational drug design. Curr Opin Drug Discov Devel 2005;8(5):590-600
   PubMed Web of Science ®Google Scholar
• Wenzel S, Wilbraham D, Fuller R, Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370(9596):1422-31
   PubMed Web of Science ®Google Scholar
• Antoniu SA. MEDI-528, an anti-IL-9 humanized antibody for the treatment of asthma. Curr Opin Mol Ther 2010;12(2):233-9
   PubMed Web of Science ®Google Scholar
• Leckie MJ, ten BA, Khan J, Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356(9248):2144-8
   PubMed Web of Science ®Google Scholar
• Kips JC, O'Connor BJ, Langley SJ, Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003;167(12):1655-9
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360(10):973-84
   PubMed Web of Science ®Google Scholar
• Tamaoki J, Kondo M, Sakai N, Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Tokyo Joshi-Idai Asthma Research Group. Lancet 2000;356(9226):273-8
   PubMed Web of Science ®Google Scholar
• Sano Y, Suzuki N, Yamada H, Effects of suplatast tosilate on allergic eosinophilic airway inflammation in patients with mild asthma. J Allergy Clin Immunol 2003;111(5):958-66
   PubMed Web of Science ®Google Scholar
• Sato T, Komai M, Iwase M, Inhibitory effect of the new orally active CCR4 antagonist K327 on CCR4+CD4+ T cell migration into the lung of mice with ovalbumin-induced lung allergic inflammation. Pharmacology 2009;84(3):171-82
   PubMed Web of Science ®Google Scholar
• Nagashima S, Yokota M, Nakai E, Synthesis and evaluation of 2-{[2-(4-hydroxyphenyl)-ethyl]amino}pyrimidine-5-carboxamide derivatives as novel STAT6 inhibitors. Bioorg Med Chem 2007;15(2):1044-55
   PubMed Web of Science ®Google Scholar
• Chiba Y, Todoroki M, Nishida Y, A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice. Am J Respir Cell Mol Biol 2009;41(5):516-24
   PubMed Web of Science ®Google Scholar
• Nagashima S, Hondo T, Nagata H, Novel 7H-pyrrolo[2,3-d] pyrimidine derivatives as potent and orally active STAT6 inhibitors. Bioorg Med Chem 2009;17(19):6926-36
   PubMed Web of Science ®Google Scholar
• Cortes JR, Perez G, Rivas MD, Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3. J Immunol 2007;179(6):3881-7
   PubMed Web of Science ®Google Scholar
• Barrett NA, Austen KF. Innate cells and T helper 2 cell immunity in airway inflammation. Immunity 2009;31(3):425-37
   PubMed Web of Science ®Google Scholar
• Fort MM, Cheung J, Yen D, IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 2001;15(6):985-95
   PubMed Web of Science ®Google Scholar
• Corrigan CJ, Wang W, Meng Q, T-helper cell type 2 (Th2) memory T cell-potentiating cytokine IL-25 has the potential to promote angiogenesis in asthma. Proc Natl Acad Sci USA 2011;108(4):1579-84
   PubMed Web of Science ®Google Scholar
• Prefontaine D, Lajoie-Kadoch S, Foley S, Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009;183(8):5094-103
   PubMed Web of Science ®Google Scholar
• Ying S, O'Connor B, Ratoff J, Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol 2005;174(12):8183-90
   PubMed Web of Science ®Google Scholar
• Yagami A, Orihara K, Morita H, IL-33 mediates inflammatory responses in human lung tissue cells. J Immunol 2010;185(10):5743-50
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Schwartz LB, Langmack EL, Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160(3):1001-8
   PubMed Web of Science ®Google Scholar
• Kamath AV, Pavord ID, Ruparelia PR, Is the neutrophil the key effector cell in severe asthma? Thorax 2005;60(7):529-30
   PubMed Web of Science ®Google Scholar
• Howarth PH, Babu KS, Arshad HS, Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005;60(12):1012-18
   PubMed Web of Science ®Google Scholar
• Morjaria JB, Chauhan AJ, Babu KS, The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008;63(7):584-91
   PubMed Web of Science ®Google Scholar
• Erin EM, Leaker BR, Nicholson GC, The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006;174(7):753-62
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Barnes PJ, Bleecker ER, A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009;179(7):549-58
   PubMed Web of Science ®Google Scholar
• Ordonez CL, Shaughnessy TE, Matthay MA, Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: Clinical and biologic significance. Am J Respir Crit Care Med 2000;161(4 Pt 1):1185-90
   PubMed Web of Science ®Google Scholar
• Dragon S, Rahman MS, Yang J, IL-17 enhances IL-1beta-mediated CXCL-8 release from human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2007;292(4):L1023-9
   PubMed Web of Science ®Google Scholar
• Laan M, Cui ZH, Hoshino H, Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999;162(4):2347-52
   PubMed Web of Science ®Google Scholar
• Ivanov S, Linden A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci 2009;30(2):95-103
   PubMed Web of Science ®Google Scholar
• Bullens DM, Truyen E, Coteur L, IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res 2006;7:135
   PubMed Web of Science ®Google Scholar
• Chapman RW, Minnicozzi M, Celly CS, A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 2007;322(2):486-93
   PubMed Web of Science ®Google Scholar
• Li JJ, Carson KG, Trivedi BK, Synthesis and structure-activity relationship of 2-amino-3-heteroaryl-quinoxalines as non-peptide, small-molecule antagonists for interleukin-8 receptor. Bioorg Med Chem 2003;11(17):3777-90
   PubMed Web of Science ®Google Scholar
• Cowburn AS, Cadwallader KA, Reed BJ, Role of PI3-kinase-dependent Bad phosphorylation and altered transcription in cytokine-mediated neutrophil survival. Blood 2002;100(7):2607-16
   PubMed Web of Science ®Google Scholar
• Ito K, Caramori G, Adcock IM. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther 2007;321(1):1-8
   PubMed Web of Science ®Google Scholar
• Kolliputi N, Waxman AB. IL-6 cytoprotection in hyperoxic acute lung injury occurs via PI3K/Akt-mediated Bax phosphorylation. Am J Physiol Lung Cell Mol Physiol 2009;297(1):L6-16
   PubMed Web of Science ®Google Scholar
• Chodniewicz D, Zhelev DV. Novel pathways of F-actin polymerization in the human neutrophil. Blood 2003;102(6):2251-8
   PubMed Web of Science ®Google Scholar
• Kroeger KM, Sullivan BM, Locksley RM. IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88- and p38alpha-dependent pathway. J Leukoc Biol 2009;86(4):769-78
   PubMed Web of Science ®Google Scholar
• Rochman Y, Leonard WJ. The role of thymic stromal lymphopoietin in CD8+ T cell homeostasis. J Immunol 2008;181(11):7699-705
   PubMed Web of Science ®Google Scholar
• Choi YS, Choi HJ, Min JK, Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009;114(14):3117-26
   PubMed Web of Science ®Google Scholar
• Lee KS, Park SJ, Kim SR, Inhibition of VEGF blocks TGF-beta1 production through a PI3K/Akt signalling pathway. Eur Respir J 2008;31(3):523-31
   PubMed Web of Science ®Google Scholar
• Lee KS, Lee HK, Hayflick JS, Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J 2006;20(3):455-65
   PubMed Web of Science ®Google Scholar
• Kettle R, Simmons J, Schindler F, Regulation of neuregulin 1beta1-induced MUC5AC and MUC5B expression in human airway epithelium. Am J Respir Cell Mol Biol 2010;42(4):472-81
   PubMed Web of Science ®Google Scholar
• Doi T, Obayashi K, Kadowaki T, PI3K is a negative regulator of IgE production. Int Immunol 2008;20(4):499-508
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 2003;3(4):317-30
   PubMed Web of Science ®Google Scholar
• Nashed BF, Zhang T, Al-Alwan M, Role of the phosphoinositide 3-kinase p110delta in generation of type 2 cytokine responses and allergic airway inflammation. Eur J Immunol 2007;37(2):416-24
   PubMed Web of Science ®Google Scholar
• Sadhu C, Masinovsky B, Dick K, Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol 2003;170(5):2647-54
   PubMed Web of Science ®Google Scholar
• American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007;175(3):235-42
   PubMed Web of Science ®Google Scholar
• Biaggioni I, Paul S, Puckett A, Caffeine and theophylline as adenosine receptor antagonists in humans. J Pharmacol Exp Ther 1991;258(2):588-93
   PubMed Web of Science ®Google Scholar
• Foukas LC, Daniele N, Ktori C, Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. J Biol Chem 2002;277(40):37124-30
   PubMed Web of Science ®Google Scholar
• Brown RA, Spina D, Page CP. Adenosine receptors and asthma. Br J Pharmacol 2008;153(Suppl 1):S446-56
   PubMed Web of Science ®Google Scholar
• Takeda M, Ito W, Tanabe M, Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase gamma-deficient mice. J Allergy Clin Immunol 2009;123(4):805-12
   PubMedGoogle Scholar
• Berndt A, Miller S, Williams O, The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol 2010;6(2):117-24
   PubMed Web of Science ®Google Scholar
• Endo D, Gon Y, Nunomura S, PI3Kgamma differentially regulates FcepsilonRI-mediated degranulation and migration of mast cells by and toward antigen. Int Arch Allergy Immunol 2009;149(Suppl 1):66-72
   PubMedGoogle Scholar
• Doukas J, Eide L, Stebbins K, Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2009;328(3):758-65
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Piggott DA, Huleatt JW, Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 2002;196(12):1645-51
   PubMed Web of Science ®Google Scholar
• Hammad H, Chieppa M, Perros F, House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med 2009;15(4):410-16
   PubMed Web of Science ®Google Scholar
• Liew FY, Xu D, Brint EK, Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005;5(6):446-58
   PubMed Web of Science ®Google Scholar
• Savov JD, Brass DM, Lawson BL, Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol 2005;289(2):L329-37
   PubMed Web of Science ®Google Scholar
• Fort MM, Mozaffarian A, Stover AG, A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol 2005;174(10):6416-23
   PubMed Web of Science ®Google Scholar
• Ii M, Matsunaga N, Hazeki K, A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol Pharmacol 2006;69(4):1288-95
   PubMed Web of Science ®Google Scholar
• Sugiyama K, Muroi M, Tanamoto K. A novel TLR4-binding peptide that inhibits LPS-induced activation of NF-kappaB and in vivo toxicity. Eur J Pharmacol 2008;594(1-3):152-6
   PubMed Web of Science ®Google Scholar
• Rosenwasser LJ. Mechanisms of IgE Inflammation. Curr Allergy Asthma Rep 2011;11(2):178-83
   PubMed Web of Science ®Google Scholar
• Holgate S, Casale T, Wenzel S, The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005;115(3):459-65
   PubMed Web of Science ®Google Scholar
• Tan RA, Corren J. Safety of omalizumab in asthma. Expert Opin Drug Saf 2011;10(3):463-71
   PubMed Web of Science ®Google Scholar
• Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol 2008;8(3):205-17
   PubMed Web of Science ®Google Scholar
• Poulsen LK, Hummelshoj L. Triggers of IgE class switching and allergy development. Ann Med 2007;39(6):440-56
   PubMed Web of Science ®Google Scholar
• Yanagihara Y, Kajiwara K, Basaki Y, Cultured basophils but not cultured mast cells induce human IgE synthesis in B cells after immunologic stimulation. Clin Exp Immunol 1998;111(1):136-43
   PubMed Web of Science ®Google Scholar
• Margolles-Clark E, Umland O, Kenyon NS, Small-molecule costimulatory blockade: organic dye inhibitors of the CD40-CD154 interaction. J Mol Med 2009;87(11):1133-43
   PubMed Web of Science ®Google Scholar
• Edwards MR, Bartlett NW, Clarke D, Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 2009;121(1):1-13
   PubMed Web of Science ®Google Scholar
• Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3(1):17-26
   PubMed Web of Science ®Google Scholar
• Lee M, Kim S, Kwon OK, Anti-inflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma. Int Immunopharmacol 2009;9(4):418-24
   PubMed Web of Science ®Google Scholar
• Chung S, Yao H, Caito S, Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys 2010;501(1):79-90
   PubMed Web of Science ®Google Scholar
• Milne JC, Lambert PD, Schenk S, Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007;450(7170):712-16
   PubMed Web of Science ®Google Scholar
• Riccaboni M, Bianchi I, Petrillo P. Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov Today 2010;15(13-14):517-30
   PubMed Web of Science ®Google Scholar
• Moriya K, Rivera J, Odom S, ER-27319, an acridone-related compound, inhibits release of antigen-induced allergic mediators from mast cells by selective inhibition of fcepsilon receptor I-mediated activation of Syk. Proc Natl Acad Sci USA 1997;94(23):12539-44
   PubMed Web of Science ®Google Scholar
• Oliver JM, Burg DL, Wilson BS, Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol. J Biol Chem 1994;269(47):29697-703
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005;115(4):791-6
   PubMed Web of Science ®Google Scholar
• Matsubara S, Li G, Takeda K, Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 2006;173(1):56-63
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Takeshita K, Shichijo M, The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther 2003;306(3):1174-81
   PubMed Web of Science ®Google Scholar
• Casale TB, Stokes JR. Immunomodulators for allergic respiratory disorders. J Allergy Clin Immunol 2008;121(2):288-96
   PubMed Web of Science ®Google Scholar
• Amin K, Ludviksdottir D, Janson C, Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group. Am J Respir Crit Care Med 2000;162(6):2295-301
   PubMed Web of Science ®Google Scholar
• Galli SJ, Tsai M, Wershil BK. The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am J Pathol 1993;142(4):965-74
   PubMed Web of Science ®Google Scholar
• Humbert M, de BF, Garcia G, Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 2009;64(8):1194-201
   PubMed Web of Science ®Google Scholar
• Bradding P. Asthma: eosinophil disease, mast cell disease, or both? Allergy Asthma Clin Immunol 2008;4(2):84-90
   PubMedGoogle Scholar
• Norman P. DP(2) receptor antagonists in development. Expert Opin Investig Drugs 2010;19(8):947-61
   PubMed Web of Science ®Google Scholar
• Stebbins KJ, Broadhead AR, Correa LD, Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur J Pharmacol 2010;638(1-3):142-9
   PubMed Web of Science ®Google Scholar
• Stock N, Volkots D, Stebbins K, Sodium [2′-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4′-(6-ethoxy-pyridin-3-yl)-6-meth oxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist. Bioorg Med Chem Lett 2011;21(3):1036-40
   PubMed Web of Science ®Google Scholar
• Gervais FG, Sawyer N, Stocco R, Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist. Mol Pharmacol 2011;79(1):69-76
   PubMed Web of Science ®Google Scholar
• Lazaar AL, Panettieri RA Jr. Is airway remodeling clinically relevant in asthma? Am J Med 2003;115(8):652-9
   PubMed Web of Science ®Google Scholar
• Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240(4854):889-95
   PubMed Web of Science ®Google Scholar
• Park SJ, Lee KS, Kim SR, Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation. J Immunol 2009;183(5):3259-67
   PubMed Web of Science ®Google Scholar
• Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol 2006;533(1-3):101-9
   PubMed Web of Science ®Google Scholar
• Glass CK, Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 2006;6(1):44-55
   PubMed Web of Science ®Google Scholar
• Burgess HA, Daugherty LE, Thatcher TH, PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005;288(6):L1146-53
   PubMed Web of Science ®Google Scholar
• Honda K, Marquillies P, Capron M, Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J Allergy Clin Immunol 2004;113(5):882-8
   PubMed Web of Science ®Google Scholar